Table 1.

Patient characteristics before ifosfamide, carboplatin, and etoposide chemotherapy

Patient characteristicsNo. patients
Age  
 Median (range) 27 (12-59)  
Response to primary therapy  
 Primary refractory 22  
 Relapsed disease 43 
Histology (WHO classification)  
 Nodular sclerosis 56 
 Mixed cellularity 7  
 Lymphocyte predominant 2 
Prior radiotherapy  
 Yes 39  
 No 26  
B symptoms pre-ICE  
 Yes 16  
 No 49  
Extranodal sites of disease pre-ICE  
 Yes 32  
 No 33  
Relapsed disease  
 CR < 1 y 13  
 CR > 1 y 30  
Prior chemotherapy  
 ABVD 32  
 MOPP/ABVD 11 
 MOPP/ABV 3  
 MOPP 3  
 Other or multiple 16 
Median no. prior regimens (range, 1-6) 1  
Prognostic model  
 0-1 factor 40  
 2 factors 15  
 3 factors 10 
Patient characteristicsNo. patients
Age  
 Median (range) 27 (12-59)  
Response to primary therapy  
 Primary refractory 22  
 Relapsed disease 43 
Histology (WHO classification)  
 Nodular sclerosis 56 
 Mixed cellularity 7  
 Lymphocyte predominant 2 
Prior radiotherapy  
 Yes 39  
 No 26  
B symptoms pre-ICE  
 Yes 16  
 No 49  
Extranodal sites of disease pre-ICE  
 Yes 32  
 No 33  
Relapsed disease  
 CR < 1 y 13  
 CR > 1 y 30  
Prior chemotherapy  
 ABVD 32  
 MOPP/ABVD 11 
 MOPP/ABV 3  
 MOPP 3  
 Other or multiple 16 
Median no. prior regimens (range, 1-6) 1  
Prognostic model  
 0-1 factor 40  
 2 factors 15  
 3 factors 10 

WHO indicates the World Health Organization; ICE, ifosfamide, carboplatin, and etoposide; CR, complete response; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone.

View Large